Cadila Healthcare has informed about inspection by USFDA of the company’s API manufacturing facility located at Dabhasa, Gujarat and company received an Establishment Inspection Report (EIR) which stated that the classification of the facility is ‘No Action Indicated (NAI)’.
The above information is a part of company’s filings submitted to BSE.